ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019
Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Site-Specific Phosphoproteomic Profiling of CAV1 Reveals Co-Regulatory Kinase Networks in Cancer Signaling.International journal of molecular sciences · 2026Article
- Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?Cell communication and signaling : CCS · 2024Review
- Article
- Click Chemistry and Radiochemistry: An Update.Bioconjugate chemistry · 2023Review
- PET and Optical Imaging of Caveolin-1 in Gastric Tumors.ACS omega · 2023Article
- Metformin-Induced Receptor Turnover Alters Antibody Accumulation in HER-Expressing Tumors.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Optimize the combination regimen of Trastuzumab and Nab-paclitaxel in HER2-positive tumors via modulating Caveolin-1 expression by lovastatin.Asian journal of pharmaceutical sciences · 2022Article
- Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.Nature communications · 2022Article
- Cancer immunomodulation using bispecific aptamers.Molecular therapy. Nucleic acids · 2022Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells.Drug design, development and therapy · 2021Article
- Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression.Frontiers in immunology · 2021Article
- Quantification of Trastuzumab-HER2 Engagement In Vitro and In Vivo.Molecules (Basel, Switzerland) · 2020Article
- Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- HarnessingProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Antibody-Targeted Imaging of Gastric Cancer.Molecules (Basel, Switzerland) · 2020Review
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.Molecular pharmaceutics · 2020Article
- Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue.Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Human epidermal growth factor receptor 2 (HER2) is used as a tumor biomarker and therapeutic target. Pertuzumab is an anti-HER2 antibody, and its binding to tumor cells requires HER2 to be present at the cell membrane. However, the cellular distribution of HER2 protein in gastric tumors is dynamic, and HER2 internalization decreases antibody binding to tumor cells. These features preclude the use of pretargeted strategies for molecular imaging and therapy. We explored the pharmacological modulation of HER2 endocytosis as a strategy to improve pertuzumab uptake in HER2-positive gastric tumors and allow the use of a pretargeted imaging approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.